Ozempic Vs Jardiance compares the efficacies of once-weekly injectable Semaglutide and Empagliflozin in lowering A1C, blood glucose, and body weight, and in patients with heart failure and kidney diseases.
Ozempic is a highly potent once-weekly injectable medicine indicated for the treatment of diabetes. It is especially indicated for obese diabetic patients with cardiovascular disease and uncontrolled blood glucose despite metformin.
Jardiance is a once-daily oral SGLT2 inhibitor that has been approved by the FDA for the treatment of Type 2 Diabetes Mellitus and heart failure.
It has also been approved for non-diabetic patients with heart failure with preserved and reduced ejection fraction (HFpEF and HFrEF).
You may also like to read: |
Ozempic Vs Jardiance: General Comparision:
Ozempic and Jardiance are both medications indicated for the treatment of diabetes. However, they belong to different classes of medicines:
Ozempic vs Jardiance comparison is tabulated below.
Feature | Ozempic | Jardiance |
Active Ingredient | Semaglutide | Empagliflozin |
Mechanism of Action |
|
|
Administration | Once-weekly subcutaneous injection | Oral tablet once daily |
FDA-Approved Indications |
|
|
Dosage Forms and Strengths | Prefilled injection pen:
| Oral tablets:
|
Half-Life | 5-7 days | 12.4 hours |
Potential Side Effects |
|
|
Contraindications |
|
|
Jardiance is also available in combination with other medications including:
- Metformin: Synjardy
- Linagliptin: Glyxambi
- Metformin and Linagliptin: TriJardy Xr
You may also like to read: |
Ozempic Vs Jardiance: Which drug is more effective for Diabetes and Weight Loss:
Ozempic is considered the most potent diabetes medication, second only to Tirzepatide as per the ADA 2023 guidelines.
SGLT2 inhibitors including Jardiance have been labeled as diabetes drugs of “Intermediate potency” by the ADA 2023 recommendations. However, they are considered to be more potent than DPP-IV inhibitors.
In clinical trials, Ozempic has been proven to be more effective than Jardiance. The table below compares the efficacies of Ozmepic and Jardiance in lowering A1C and body weight:
Feature | Ozempic | Jardiance |
A1C Reduction | 1.0%-1.8% | 0.5%-1.0% |
Weight Loss | 5%-10% of the baseline body weight. | 2%-4% of the baseline body weight. |
Ozempic has an A1C lowering effect almost double that of Jardiance. Similarly, the weight loss effects of Ozempic are also 2 to 3 times greater than that of Jardiance.
You may also like to read: |
Effect of Ozempic Vs Jardiance on Blood Glucose:
Ozempic lowers both fasting and prandial blood glucose as a result of its insulin-secretory effects. However, Jardiance has a greater effect on fasting blood glucose than prandial blood glucose.
Here is a table comparing the effects of Jardiance Vs Ozempic on blood glucose and insulin requirements:
Feature | Ozempic | Jardiance |
Fasting Blood Glucose | The mean change from baseline in fasting plasma glucose:
| The mean change from baseline in fasting plasma glucose levels was:
|
Prandial Blood Glucose | The mean change from baseline in 2-hour postprandial glucose levels was:
| Not studied |
A1C Reduction | Average A1C reduction:
| Average A1C reduction:
In clinical trials:
|
Insulin Requirements | Reduces insulin requirements:
| Does not significantly impact insulin requirements. |
Hypoglycemia | Does not cause hypoglycemia but there is a risk if used in combination with insulin and sulfonylureas | The risk of hypoglycemia is minimal. |
It is important to note that both Ozempic and Jardiance do not cause hypoglycemia. Jardiance in particular is not associated with hypoglycemia even if used in combination with insulin or sulfonylureas.
You may also like to read: |
Ozempic Vs Jardiance in Heart failure and Kidney disease:
Both Ozempic and Jardiance have been proven to improve the outcomes of patients with heart failure and kidney diseases.
Ozmepic is considered to be superior to Jardiance in reducing the risks of atherosclerotic cardiovascular diseases and stroke.
On the other hand, Jardiance is superior in patients with heart failure. Because of its superior efficacy, it has been approved for heart failure with preserved and reduced ejection fraction (HFpEF and HFrEF).
Here is a table comparing the efficacies of Ozempic and Jardiance in patients with cardiovascular diseases:
Feature | Ozempic | Jardiance |
Cardiovascular Effects | Trial: SUSTAIN 6 trial Patients: T2DM and high cardiovascular risk Outcome: Cardiovascular safety Results: 26% reduction in the risk of major adverse cardiovascular events (MACE) (primarily stroke) | Trial: EMPA-REG OUTCOME trial Patients: T2DM and established CVD Outcome: Cardiovascular safety Results: 14% reduction in the risk of MACE (primarily cardiovascular death) |
Efficacy in Heart Failure | 35% reduction in the risk of hospitalization due to heart failure compared to a placebo [Ref] | 25% reduction in the risk of hospitalization due to heart failure compared to a placebo [Ref] |
Hospitalization due to Heart Failure | Lower the risk of hospitalization due to heart failure by 35% | Lower the risk of hospitalization due to heart failure by 25% |
Renal Outcomes | 33% reduction in the risk of new or worsening nephropathy compared to placebo [Ref] | 39% reduction in the risk of new or worsening nephropathy compared to placebo [Ref] 50% reduction in the risk of kidney failure, dialysis, or kidney transplantation compared to a placebo [Ref] |
Stroke | 39% reduction in the risk of nonfatal stroke compared to placebo [Ref] | 24% reduction in the risk of stroke compared to placebo [Ref] |
Death | Significant reduction in the risk of all-cause mortality compared to placebo. | 32% reduction in the risk of cardiovascular death and a 38% reduction in the risk of all-cause mortality compared to placebo [Ref] In the EMPEROR-Reduced trial, Jardiance was associated with a 27% reduction in the risk of cardiovascular death compared to placebo. |
You may also like to read: |
In conclusion:
Both Jardiance and Ozempic are potent drugs for the treatment of diabetes type 2. Ozmepic is more potent in lowering blood glucose and body weight.
Jardiance, on the other hand, is a better option for patients with heart failure and kidney disease.
Condition | Winner:Ozempic or Jardiance |
Diabetes | Ozempic |
Hypertension | Jardiance |
Obesity | Ozempic |
Atherosclerotic Cardiovascular diseases | Ozempic |
Heart failure | Jardiance |
Stroke | Ozempic |
Kidney diseases | Jardiance |
You may also like to read: |